A/S Novo Nordisk (responsible for batch release of finished medicinal product; preparation, filling into primary packaging, lyophilization and inspection of finished medicinal product, quality control (microbiological tests) of finished medicinal product, addition of scale to injection pen, labeling and secondary packaging of finished medicinal product; preparation, filling into primary packaging, lyophilization and inspection of finished medicinal product, quality control (microbiological tests) of finished medicinal product)
UkraineAll drugs from this manufacturer
-
The drug is used for the treatment and prevention of bleeding in patients with hemophilia A (congenital factor VIII deficiency).
Dosage form: powder and solvent for injection solution
Active substance Dosage turoctocog alfa pegol 500 IU ATC: B02BD02
-
The drug is used for the treatment and prevention of bleeding in patients with hemophilia A (congenital factor VIII deficiency).
Dosage form: powder and solvent for injection solution
Active substance Dosage turoctocog alfa pegol 1000 IU ATC: B02BD02
-
The drug is used for the treatment and prevention of bleeding in patients with hemophilia A (congenital factor VIII deficiency).
Dosage form: powder and solvent for injection solution
Active substance Dosage turoctocog alfa pegol 1500 IU ATC: B02BD02
-
The drug is used for the treatment and prevention of bleeding in patients with hemophilia A (congenital factor VIII deficiency).
Dosage form: powder and solvent for injection solution
Active substance Dosage turoctocog alfa pegol 2000 IU ATC: B02BD02
-
The drug is used for the treatment and prevention of bleeding in patients with hemophilia A (congenital factor VIII deficiency).
Dosage form: powder and solvent for injection solution
Active substance Dosage turoctocog alfa pegol 3000 IU ATC: B02BD02